The Changing Landscape of Carrier Screening: Expanding Technology and Options?

Overview

Journal Health Matrix Clevel

Specialty Health Services

Date 2013 Jul 2

PMID 23808097

Citations 8

Authors

Michelle L McGowan

Deborah Cho

Richard R Sharp

Affiliations

Soon will be listed here.

Citing Articles

Societal implications of expanded universal carrier screening: a scoping review.

van den Heuvel L, van den Berg N, Janssens A, Birnie E, Henneman L, Dondorp W Eur J Hum Genet. 2022; 31(1):55-72.

PMID: 36097155 PMC: 9822904. DOI: 10.1038/s41431-022-01178-8.

The evolving landscape of expanded carrier screening: challenges and opportunities.

Kraft S, Duenas D, Wilfond B, Goddard K Genet Med. 2018; 21(4):790-797.

PMID: 30245516 PMC: 6752283. DOI: 10.1038/s41436-018-0273-4.

Structurating Expanded Genetic Carrier Screening: A Longitudinal Analysis of Online News Coverage.

Canary H, Clark Y, Holton A J Health Commun. 2018; 23(6):534-541.

PMID: 29799365 PMC: 6252291. DOI: 10.1080/10810730.2018.1477884.

Pre- and post-testing counseling considerations for the provision of expanded carrier screening: exploration of European geneticists' views.

Janssens S, Chokoshvili D, Vears D, De Paepe A, Borry P BMC Med Ethics. 2017; 18(1):46.

PMID: 28764782 PMC: 5539885. DOI: 10.1186/s12910-017-0206-9.

Precisely Where Are We Going? Charting the New Terrain of Precision Prevention.

Meagher K, McGowan M, Settersten Jr R, Fishman J, Juengst E Annu Rev Genomics Hum Genet. 2017; 18:369-387.

PMID: 28441061 PMC: 6203331. DOI: 10.1146/annurev-genom-091416-035222.

References

Watson M, Cutting G, Desnick R, Driscoll D, Klinger K, Mennuti M . Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med. 2004; 6(5):387-91. PMC: 3110945. DOI: 10.1097/01.gim.0000139506.11694.7c. View

Kronn D, Jansen V, Ostrer H . Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY. Arch Intern Med. 1998; 158(7):777-81. DOI: 10.1001/archinte.158.7.777. View

McConkie-Rosell A, Heise E, Spiridigliozzi G . Influence of genetic risk information on parental role identity in adolescent girls and young women from families with fragile X syndrome. J Genet Couns. 2011; 21(1):59-71. PMC: 3506010. DOI: 10.1007/s10897-011-9391-8. View

Gross S, Pletcher B, Monaghan K . Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med. 2008; 10(1):54-6. PMC: 3110977. DOI: 10.1097/GIM.0b013e31815f247c. View

Srinivasan B, Evans E, Flannick J, Scott Patterson A, Chang C, Pham T . A universal carrier test for the long tail of Mendelian disease. Reprod Biomed Online. 2010; 21(4):537-51. DOI: 10.1016/j.rbmo.2010.05.012. View

Jackson L, Pyeritz R . Molecular technologies open new clinical genetic vistas. Sci Transl Med. 2011; 3(65):65ps2. DOI: 10.1126/scitranslmed.3002064. View

Clayton E, Hannig V, Pfotenhauer J, Parker R, Campbell 3rd P, Phillips 3rd J . Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening. Am J Hum Genet. 1996; 58(3):617-27. PMC: 1914565. View

Pletcher B, Gross S, Monaghan K, Driscoll D, Watson M . The future is now: carrier screening for all populations. Genet Med. 2008; 10(1):33-6. DOI: 10.1097/GIM.0b013e31815f5934. View

Bell C, Dinwiddie D, Miller N, Hateley S, Ganusova E, Mudge J . Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med. 2011; 3(65):65ra4. PMC: 3740116. DOI: 10.1126/scitranslmed.3001756. View

10.

Morgan M, Driscoll D, Mennuti M, Schulkin J . Practice patterns of obstetrician-gynecologists regarding preconception and prenatal screening for cystic fibrosis. Genet Med. 2004; 6(5):450-5. DOI: 10.1097/01.gim.0000139509.04177.4b. View

11.

Rothman B . Not all that glitters is gold. Hastings Cent Rep. 1992; 22(4):S11-5. View

12.

Edelson P . The Tay-Sachs disease screening program in the U.S. as a model for the control of genetic disease: an historical view. Health Matrix Clevel. 1997; 7(1):125-33. View

13.

Langfelder-Schwind E, Kloza E, Sugarman E, Pettersen B, Brown T, Jensen K . Cystic fibrosis prenatal screening in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2005; 14(1):1-15. DOI: 10.1007/s10897-005-1496-5. View

14.

Prior T . Carrier screening for spinal muscular atrophy. Genet Med. 2008; 10(11):840-2. PMC: 3110347. DOI: 10.1097/GIM.0b013e318188d069. View

15.

Lyerly A, Mitchell L, Armstrong E, Harris L, Kukla R, Kuppermann M . Risks, values, and decision making surrounding pregnancy. Obstet Gynecol. 2007; 109(4):979-84. DOI: 10.1097/01.AOG.0000258285.43499.4b. View

16.

Eng C, Schechter C, Robinowitz J, Fulop G, Burgert T, Levy B . Prenatal genetic carrier testing using triple disease screening. JAMA. 1997; 278(15):1268-72. View

17.

Botkin J . Assessing the new criteria for newborn screening. Health Matrix Clevel. 2009; 19(1):163-86. View

18.

Ormond K, Iris M, Banuvar S, Minogue J, Annas G, Elias S . What do patients prefer: informed consent models for genetic carrier testing. J Genet Couns. 2007; 16(4):539-50. DOI: 10.1007/s10897-007-9094-3. View

19.

Juengst E, Settersten Jr R, Fishman J, McGowan M . After the revolution? Ethical and social challenges in 'personalized genomic medicine'. Per Med. 2013; 9(4):429-439. PMC: 3646379. DOI: 10.2217/pme.12.37. View

20.

Lim S . Protecting the unborn as modern day eugenics. Health Matrix Clevel. 2009; 18(1):127-36. View